1 interaction related to feverfew
Feverfew (Tanacetum parthenium) inhibits platelet aggregation in laboratory studies via its parthenolide sesquiterpene lactones, which creates a theoretical, additive bleeding concern alongside warfarin. The evidence is bench/in-vitro only: systematic reviews classify feverfew's anticoagulant signal as low-level laboratory evidence, and there are no published human case reports of bleeding when feverfew is combined with warfarin. The cautious, mechanism-based approach is to avoid concentrated feverfew supplements while on warfarin and to disclose use to the clinician managing anticoagulation.
